Thyroid Cancer in Kazakhstan: Component Analysis of Incidence Dynamics.


Journal

Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625

Informations de publication

Date de publication:
01 09 2019
Historique:
received: 21 05 2019
entrez: 27 9 2019
pubmed: 27 9 2019
medline: 15 2 2020
Statut: epublish

Résumé

Background: The International Agency for Research on Cancer (IARC) reports that 567,000 new cases of thyroid cancer (TC) were registered in the world in 2018, and the age-standardized incidence rate was 6.7 per 100,000. The Global Cancer Observation forecasts a 35% growth in the number of new cases worldwide by 2040. The number of patients with TC in Kazakhstan is also increasing steadily. This investigation was the first epidemiological study of TC trends by component analysis among the population of Kazakhstan. This paper presents the results of the component analysis of TC incidence trends in Kazakhstan. Methods: The study covers primary data of TC cases (ICD 10 – C73) registered throughout Kazakhstan from 2009 to 2018. TC incidence trends were evaluated using component analysis according to the methodological recommendations. Results: 5,559 new TC cases were registered during the 10-year study period. The average age of patients was 52.0±0.2 years, the average annual age-standardized rate in 2009-2018 was 3.3±0.20/0000, with a constant upward trend (Т=+6.6%). According to the component analysis results, the increase in incidence was mainly due to the combined effect of the two factors: the increased disease risk (ΔR=+61.7%), and the population growth (ΔP=+15.4%). Conclusion: The noted increase in incidence was mainly caused by the changes in risk factors, such as the worsening environmental aspects and the increase in detection of clinically non-manifesting cases. The results of the study shall be taken into account when planning anticancer activities for TC.

Identifiants

pubmed: 31554390
doi: 10.31557/APJCP.2019.20.9.2875
pmc: PMC6976859
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2875-2880

Références

Curr Opin Endocrinol Diabetes Obes. 2017 Oct;24(5):332-336
pubmed: 28692457
Int J Cancer. 2013 Mar 1;132(5):1222-6
pubmed: 22847218
Cancer Res Treat. 2012 Mar;44(1):11-24
pubmed: 22500156
Thyroid. 2018 Jan;28(1):11-22
pubmed: 28954584
Iran J Public Health. 2016 Aug;45(8):1012-1019
pubmed: 27928527
Nat Rev Cancer. 2006 Jan;6(1):63-74
pubmed: 16372017
Cancer. 2015 Feb 1;121(3):457-66
pubmed: 25351557
Asian Pac J Cancer Prev. 2013;14(3):1945-9
pubmed: 23679297
Nature. 1992 Sep 3;359(6390):21
pubmed: 1522879
Asian Pac J Cancer Prev. 2016;17(1):377-80
pubmed: 26838242
Radiat Res. 2016 May;185(5):473-84
pubmed: 27128740
Int J Cancer. 2015 May 1;136(9):2187-95
pubmed: 25284703
Asian Pac J Cancer Prev. 2015;16(6):2289-93
pubmed: 25824752
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
J Clin Endocrinol Metab. 2017 Jul 1;102(7):2207-2217
pubmed: 28368520
BMJ. 2016 Nov 30;355:i5745
pubmed: 27903497

Auteurs

Nurbek Igissinov (N)

Astana Medical University, Nur-Sultan, Kazakhstan. Email:n.igissinov@gmail.com
International High School of Medicine, Bishkek, Kyrgyzstan.
Central Asian Cancer Institute, Nur-Sultan, Kazakhstan.
Eurasian Institute for Cancer Research, Bishkek, Kyrgyzstan.

Saken Kozhakhmetov (S)

Astana Medical University, Nur-Sultan, Kazakhstan. Email:n.igissinov@gmail.com
Central Asian Cancer Institute, Nur-Sultan, Kazakhstan.

Marzhan Zhantubetova (M)

Astana Medical University, Nur-Sultan, Kazakhstan. Email:n.igissinov@gmail.com
Central Asian Cancer Institute, Nur-Sultan, Kazakhstan.

Gulnur Igissinova (G)

Central Asian Cancer Institute, Nur-Sultan, Kazakhstan.
National Medical University, Almaty, Kazakhstan.

Zarina Bilyalova (Z)

Central Asian Cancer Institute, Nur-Sultan, Kazakhstan.

Gulnur Akpolatova (G)

Astana Medical University, Nur-Sultan, Kazakhstan. Email:n.igissinov@gmail.com

Vladimir Lyust (V)

Astana Medical University, Nur-Sultan, Kazakhstan. Email:n.igissinov@gmail.com

Sarsembi Koblandin (S)

Astana Medical University, Nur-Sultan, Kazakhstan. Email:n.igissinov@gmail.com

Dulat Turebayev (D)

Astana Medical University, Nur-Sultan, Kazakhstan. Email:n.igissinov@gmail.com

Kairat Adaibayev (K)

Astana Medical University, Nur-Sultan, Kazakhstan. Email:n.igissinov@gmail.com

Ardak Omarbekov (A)

Astana Medical University, Nur-Sultan, Kazakhstan. Email:n.igissinov@gmail.com

Dinara Tarzhanova (D)

Astana Medical University, Nur-Sultan, Kazakhstan. Email:n.igissinov@gmail.com

Akmaral Zhantureyeva (A)

Astana Medical University, Nur-Sultan, Kazakhstan. Email:n.igissinov@gmail.com

Askar Esseyev (A)

Astana Medical University, Nur-Sultan, Kazakhstan. Email:n.igissinov@gmail.com
Central Asian Cancer Institute, Nur-Sultan, Kazakhstan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH